

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

GUIDELINES EQUALITY IMPACT ASSESSMENT FORM

SCOPING

**GUIDELINES EQUALITY IMPACT ASSESSMENT FORM:
SCOPING**

Guideline title: Dyspepsia and gastro-oesophageal reflux disease: investigation and management of dyspepsia, symptoms suggestive of GORD, or both.

1. Have relevant equality issues been identified during scoping?

- Please state briefly any relevant issues identified and the plans to tackle them during development
- For example
 - if the effect of an intervention may vary by ethnic group, what plans are there to investigate this?
 - If a test is likely to be used to define eligibility for an intervention, how will the GDG consider whether all groups can complete the test?

The guideline considers all people who receive healthcare in all settings within NHS services irrespective of gender, ethnicity, disability, religion or beliefs, sexual orientation and gender identity or socio-economic status. Where appropriate, the developers will consider these points when making recommendations for this guideline.

2. If there are exclusions listed in the scope (for example, populations, treatments or settings) are these justified?

- Are the reasons legitimate? (they do not discriminate against a particular group)
- Is the exclusion proportionate (i.e. the greater the relevance of a function to equality, the greater the regard which should be paid to equality issues) or is there another approach?

Children (younger than 18 years)

- GORD - this group will be covered by the GORD in children guideline to be developed by the National Collaborating Centre for Women and Children
- Dyspepsia – it is considered a rare clinical problem within this group

3. Have relevant bodies and stakeholders been consulted?

- Have relevant bodies been consulted?
- Have comments from stakeholders that highlight potential for discrimination or promoting equality been considered in the final scope?

Yes. A stakeholder workshop was held where representatives from relevant stakeholder groups attended. Following the workshop the scope has been revised to incorporate stakeholder comment-s. In addition all registered stakeholders for this guideline are invited to comment on the scope during the consultation period and the scope will be revised as appropriate to incorporate these comments.

Signed:

Nicole Elliott

ICG Associate Director

Peter Barry

GDG Chair

Approved and signed off:

Sharon Summers-Ma

CCP Lead